Fresenius Medical Care uses cookies on this website to enhance the user experience and provide the best possible service. By continuing to browse the website, you consent to our use of cookies. For details see our privacy policy.
On March 11, 2019 we announced to commence our share buy-back program on the basis of the authorization by the General Meeting 2016.
In the context of this share buy-back program, the company repurchased 3.7 million ordinary shares at a total purchase price (excluding ancillary transaction costs) of 270 million Euro in the period from 12 March 2019 until and including 10 May 2019.
Up to a maximum of 12 million ordinary shares will be repurchased at a total purchase price (excluding ancillary transaction costs) of up to 660 million Euro (approximately 745 million U.S. Dollar) in the period from 17 June 2019 until and including 17 June 2020.
The own shares repurchased by the Company will be used for the sole purpose of reducing the registered share capital by cancellation of the repurchased own shares.
In the following, we inform you about the progress of the share buy-back program.
On May 25, 2018 we announced to commence our share buy-back program on the basis of the authorization by the General Meeting 2016.
In the context of this share buy-back program, up to a maximum of 431,000 ordinary shares of Fresenius Medical Care will be repurchased at a total purchase price (excluding ancillary transaction costs) of up to 39 million Euro (approximately 46.5 million U.S. Dollar) in the period from May 28, 2018 until and including June 20, 2018.
In the following, we inform you about the progress of the share buy-back program.
The own shares repurchased by the Company will be used for the sole purpose of reducing the registered share capital by cancellation of the repurchased own shares in order to neutralize the dilution from the Stock Option Plan 2011.
On December 8, 2017 we announced to commence our share buy-back program on the basis of the authorization by the General Meeting 2016.
In the context of this share buy-back program, up to a maximum of 660,000 ordinary shares of Fresenius Medical Care will be repurchased at a total purchase price (excluding ancillary transaction costs) of up to 61 million Euro (approximately 72 million U.S. Dollar) in the period from December 11, 2017 until and including December 22, 2017.
In the following, we inform you about the progress of the share buy-back program.
The own shares repurchased by the Company will be used for the sole purpose of reducing the registered share capital by cancellation of the repurchased own shares in order to neutralize the dilution from the Stock Option Plan 2011.
On May 20, 2013 we commenced, as announced on May 17, 2013, our share buy-back program on the basis of the authorization by the Annual General Meeting 2011.
In the context of this share buy-back program, ordinary shares of Fresenius Medical Care in the total amount of €385 million (excluding fees) were repurchased in the period from May 20, 2013 until August 14, 2013. Accordingly, the share buy-back program was fully completed on August 14, 2013. The program was financed from cash flow and existing credit facilities.
In the following we inform you about the number of shares acquired in the context of the share buy-back program.
The own shares acquired by the company will be used to serve the sole purposes of either reducing the registered share capital of the company by cancellation of the acquired own shares, or fulfilling employee participation programs of the company.
